Journal
CANCER TREATMENT REVIEWS
Volume 40, Issue 1, Pages 31-40Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2013.07.008
Keywords
Prostate cancer; Androgen receptor; Apoptosis; Necrosis; Autophagy; Anoikis; Entosis; Cell death
Categories
Funding
- NIH [CA127300, CA156700]
- Taiwan Department of Health Clinical Trial and Research Center of Excellence Grant [DOH99-TD-B-111-004]
- National Basic Research Program of China [2012CB518304]
Ask authors/readers for more resources
Androgen/androgen receptor (AR) signaling plays pivotal roles in the prostate development and homeostasis as well as in the progression of prostate cancer (PCa). Androgen deprivation therapy (ADT) with anti-androgens remains as the main treatment for later stage PCa, and it has been shown to effectively suppress PCa growth during the first 12-24 months. However, ADT eventually fails and tumors may re-grow and progress into the castration resistant stage. Recent reports revealed that AR might play complicated and even opposite roles in PCa progression that might depend on cell types and tumor stages. Importantly, AR may influence PCa progression via differential modulation of various cell deaths including apoptosis, anoikis, entosis, necrosis, and autophagic cell deaths. Targeting AR may induce PCa cell apoptosis, autophagic cell deaths and programmed necrosis, yet targeting AR may suppress cell deaths via anoikis and entosis that may potentially lead to increased metastasis. These differential functions of AR in various types of PCa cell death might challenge the current ADT with anti-androgens treatment. Further detailed dissection of molecular mechanisms by which AR modulates different PCa cell deaths will help us to develop a better therapy to battle PCa. (C) 2013 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available